FIG 4.

HIV-1-specific antibody responses and ADCC following 2 to 12 months of ATI. We obtained plasma samples from subjects in the SMART trial who either continued receiving ART (ART; n = 22) or interrupted ART (ATI; n = 30) for 12 months. (A) HIV-1 viral loads. (B) Concentrations of gp120-specific IgG antibodies. (C) Levels of gp120-specific antibodies that bind dimeric FcγRIIIa. (D) Anti-HIV-1 ADCC responses in a subset of subjects who continued receiving ART (n = 8) or underwent ATI (n = 10) for 12 months. The ADCC data were averaged from 2 independent experiments. Red lines depict the medians of each group. Statistical analyses between baseline and the different time points were performed using the Friedman test followed by Dunn's posttest. *, P < 0.05; **, P < 0.01, ***, P < 0.001; ****, P < 0.0001.